IDEAYA Biosciences announced positive topline results from the Phase 2/3 OptimUM-02 trial of darovasertib combined with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma, showing a 58% reduction in disease progression risk and improved progression-free survival. The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026, aiming for accelerated approval under the Real-Time Oncology Review program. Additional clinical updates for other pipeline candidates are expected in H2 2026, and IDEAYA maintains a strong cash reserve of approximately $973 million, supporting operations into 2030.
Zoom Video Communications has appointed Carlos Quaderi as Head of Asia Pacific (APAC), effective August 1, 2026. Quaderi will oversee Zoom's go-to-market strategy across APAC, including Australia, New Zealand, Asia, India, and Korea (excluding Japan)...
FDH Aero and LATECOERE have entered a global supply agreement, making FDH Hardware a key supplier for LATECOERE's manufacturing sites in Brazil, Bulgaria, France, the Czech Republic, Tunisia, and Morocco. This partnership aligns FDH Aero's hardware p...
YieldMax ETFs announced weekly distributions for its Group 1 option income ETFs, with payments scheduled for July 23, 2026. The distributions vary by ETF, with rates ranging from about 26% to over 60% annualized based on recent NAV, reflecting income...
BioNTech SE will announce its second quarter 2026 financial results on August 4, 2026, followed by a webcast and conference call for investors and the public. The event will cover financial performance and updates on BioNTech's oncology pipeline, whi...
Investec Bank plc, acting as advisor and joint broker to Advanced Medical Solutions Group plc, disclosed its share dealings on July 20, 2026. The bank purchased 1,786,258 ordinary shares and sold 1,952,322 ordinary shares at prices around 279 to 280 ...
